Aubrey Whelan

3 weeks ago | dailygazette.com | Aubrey Whelan

PHILADELPHIA — KJ Muldoon, an infant with a life-threatening metabolic disorder who received a pioneering gene-editing therapy at Children’s Hospital of Philadelphia, went home Tuesday after 307 days at the hospital, CHOP announced. KJ risked irreparable brain damage from his condition, called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which his liver could not process protein. CPS1 deficiency is deadly in more than half of cases. kAms@4E@CD 2E rw~! C2A:5=J 56G6=@A65 H:E9:?

3 weeks ago | swoknews.com | Aubrey Whelan

PHILADELPHIA — KJ Muldoon, an infant with a life-threatening metabolic disorder who received a pioneering gene-editing therapy at Children’s Hospital of Philadelphia, went home Tuesday after 307 days at the hospital, CHOP announced. KJ risked irreparable brain damage from his condition, called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which his liver could not process protein. CPS1 deficiency is deadly in more than half of cases. kAms@4E@CD 2E rw~! C2A:5=J 56G6=@A65 H:E9:?

3 weeks ago | inquirer.com | Aubrey Whelan

KJ Muldoon, the infant with a life-threatening metabolic disorder who received a pioneering gene-editing therapy at Children’s Hospital of Philadelphia, went home Tuesday after 307 days at the hospital, CHOP announced. KJ risked irreparable brain damage from his condition, called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which his liver could not process protein. CPS1 deficiency is deadly in more than half of cases.

3 weeks ago | inquirer.com | Sean Walsh |Aubrey Whelan

A reply-all email. A misunderstanding. Insincere exclamation points. Screen shots of an email exchange between Philadelphia City Council members last week are making their way around City Hall, and they have all the trappings of a cringe-worthy office communication gone wrong. But the topics discussed — mental health and addiction services — were more grave than typical water-cooler gossip.

3 weeks ago | inquirer.com | Aubrey Whelan

Temple University physician Rohit Soans worries that patients using weight-loss medications may be considering risky options to keep taking these popular drugs. As new restrictions on popular GLP-1 weight-loss drugs like Ozempic kicked in this month, social media forums are being flooded with worried consumers unsure how they would get the drugs, which cost hundreds without insurance coverage. Some recommend seeking them from other countries, outside of federal regulation.